Table 1 Patient Demographics and Baseline Clinical Characteristics.
Steroid-Refractory Acute GVHD (n = 113) | Steroid-Dependent Acute GVHD (n = 55) | Total Population(N = 168) | |
|---|---|---|---|
Age, y, mean (SD) | 53.6 (13.2) | 57.3 (10.5) | 54.8 (12.5) |
Age groups, y, n (%) | |||
<18 | 3 (2.7) | 0 | 3 (1.8) |
18–40 | 19 (16.8) | 4 (7.3) | 23 (13.7) |
>40 | 91 (80.5) | 51 (92.7) | 142 (84.5) |
Male, n (%) | 69 (61.1) | 38 (69.1) | 107 (63.7) |
Race, n (%) | |||
White | 96 (85.0) | 50 (90.9) | 146 (86.9) |
Black | 4 (3.5) | 3 (5.5) | 7 (4.2) |
Other | 5 (4.4) | 1 (1.8) | 6 (3.6) |
Unknown | 7 (6.2) | 0 | 7 (4.2) |
Insurance status at transplant,* n (%) | |||
Private or group health insurance | 77 (68.1) | 38 (69.1) | 115 (68.5) |
Medicare | 32 (28.3) | 16 (29.1) | 48 (28.6) |
Medicaid | 10 (8.8) | 1 (1.8) | 11 (6.5) |
Other | 7 (6.2) | 3 (5.5) | 10 (6.0) |
Underlying malignancy, n (%) | |||
Acute myeloid leukemia | 40 (35.4) | 19 (34.5) | 59 (35.1) |
Myelodysplastic syndrome | 22 (19.5) | 10 (18.2) | 32 (19.0) |
Acute lymphoid leukemia | 18 (15.9) | 9 (16.4) | 27 (16.1) |
Chronic myeloid leukemia | 8 (7.1) | 4 (7.3) | 12 (7.1) |
Multiple myeloma | 8 (7.1) | 3 (5.5) | 11 (6.5) |
Non-Hodgkin lymphoma | 6 (5.3) | 5 (9.1) | 11 (6.5) |
Other | 11 (9.7) | 5 (9.1) | 16 (9.5) |
Remission status of primary disease at transplant, n (%) | |||
Complete remission | 74 (65.5) | 33 (60.0) | 107 (63.7) |
Stable disease | 16 (14.2) | 9 (16.4) | 25 (14.9) |
Partial remission | 11 (9.7) | 7 (12.7) | 18 (10.7) |
Progressive disease | 5 (4.4) | 4 (7.3) | 9 (5.4) |
Not assessed | 7 (6.2) | 2 (3.6) | 9 (5.4) |
HCT Comorbidity Index at transplant, n (%) | |||
Low risk (0) | 16 (14.2) | 7 (12.7) | 23 (13.7) |
Intermediate risk (1–2) | 31 (27.4) | 18 (32.7) | 49 (29.2) |
High risk (≥3) | 63 (55.8) | 26 (47.3) | 89 (53.0) |
Unknown | 3 (2.7) | 4 (7.3) | 7 (4.2) |
Year of transplant, n (%) | |||
2014 | 29 (25.7) | 14 (25.5) | 43 (25.6) |
2015 | 63 (55.8) | 29 (52.7) | 92 (54.8) |
2016 | 21 (18.6) | 12 (21.8) | 33 (19.6) |
Transplant setting,† n (%) | |||
Inpatient | 99 (87.6) | 54 (98.2) | 153 (91.1) |
Outpatient | 11 (9.7) | 1 (1.8) | 12 (7.1) |
Graft source, n (%) | |||
Peripheral blood | 81 (71.7) | 43 (78.2) | 124 (73.8) |
Umbilical cord blood | 16 (14.2) | 6 (10.9) | 22 (13.1) |
Bone marrow | 12 (10.6) | 6 (10.9) | 18 (10.7) |
Unknown | 4 (3.5) | 0 | 4 (2.4) |
HLA donor type, n (%) | |||
Matched, unrelated | 61 (54.0) | 25 (45.5) | 86 (51.2) |
Matched, related | 31 (27.4) | 8 (14.5) | 39 (23.2) |
Mismatched, unrelated | 16 (14.2) | 8 (14.5) | 24 (14.3) |
Mismatched, related | 4 (3.5) | 14 (25.5) | 18 (10.7) |
Unknown | 1 (0.9) | 0 | 1 (0.6) |
Transplant conditioning regimen, n (%) | |||
Myeloablative | 58 (51.3) | 14 (25.5) | 72 (42.9) |
Reduced intensity | 27 (23.9) | 26 (47.3) | 53 (31.5) |
Nonmyeloablative | 28 (24.8) | 15 (27.3) | 43 (25.6) |
GVHD prophylaxis therapy,‡ n (%) | |||
Tacrolimus-based | 74 (71.8) | 34 (61.8) | 108 (74.0) |
Methotrexate | 50 (48.5) | 17 (30.9) | 67 (45.9) |
Mycophenolate | 44 (42.7) | 23 (41.8) | 67 (45.9) |
Cyclosporine-based | 28 (27.2) | 7 (12.7) | 35 (24.0) |
Antithymocyte globulin | 13 (12.6) | 8 (14.5) | 21 (14.4) |
High-dose cyclophosphamide (posttransplant) | 1 (1.0) | 9 (16.4) | 10 (6.8) |
Sirolimus | 1 (1.0) | 5 (9.1) | 6 (4.1) |
Other | 2 (1.9) | 7 (12.7) | 9 (6.2) |
Duration of follow-up since transplant,§ d, mean (SD) | 504.9 (469.3) | 497.0 (472.0) | 502.3 (468.8) |
